Great Post by Fat Albert at the swamp:
Anyone see a connection?
Leo puts out a PR about Kevetrin's ability to arrest cell growth in AML cells. Kevetrin further shown to exhibit preferential cytotoxic activity against leukemia blast cells while largely not affecting the immune microenvironment, supporting a less toxic drug profile.
As a gene-based therapy, should Kevetrin demonstrate efficacy in clinical testing, its regulatory pathway to approval might be expedited. The Food and Drug Administration (FDA) has signaled strong support for development of gene therapies. Two gene therapies for cancers of the blood (Kymriah and Yescarta) were approved for genetically-driven diseases based primarily on results from mid-stage, single-arm, open-label clinical trials. FDA’s efficacy determination for Kymriah was based on 92 evaluable patients, and 108 evaluable patients for Yescarta.
Yescarta/Tecartus used in conjunction within REMS program. Owned by Kite Pharma, Inc. a Gilead Company.
* Gilead owns Remdesivir which works great in conjunction with Brilacidin.
* Gilead is in the Lymphoma fighting business through Kite Pharma (Tecartus against MCL).
* Kevetrin shown to be a promising therapeutic against TP53-mutant AML.
* B has been proven to help against cytokines storms
* Gilead just purchased Immunomedics which is highly vested in the research to fight different types of cancers.
IPIX has the most promising p53 modulator and the most promising defensin-mimetic.
This is a match made in heaven!!!! Gilead can further enhance it's lymphoma fighting pipeline with Keventrin while utilizing Brilacidin in conjunction with Remdesivir and their AML and MCL drugs that have cytokines storm reactions.
I think Gilead is making a play!